This study sought to determine whether known genetic, drug, dietary, compliance, and lifestyle factors affecting clopidogrel absorption and metabolism fully account for the variability in clopidogrel pharmacokinetics and pharmacodynamics.
Antiplatelet therapy with clopidogrel reduces coronary events in patients with acute coronary syndrome (1) . However, platelet inhibition by clopidogrel is highly variable, and patients with reduced platelet inhibition have an increased risk for major adverse cardiovascular events (2) . Esterases degrade ϳ85% of absorbed clopidogrel, leaving only 15% to be converted by the cytochrome P-450 family of enzymes (3, 4) and possibly paraoxonase 1 (PON1) (5) , to the active metabolite required for inhibition of the platelet adenosine diphosphate (ADP) receptor, P2Y 12 . Variability in clopidogrel pharmacokinetics and pharmacodynamics has been attributed to absorption (e.g., diet or polymorphisms in the transporter molecule ABCB1 [6 -8] ), smoking (which alters cytochrome P-450 levels) (9, 10) , polymorphisms in CYP2C19 (8) and/or PON1 (5), drug-drug interactions (e.g., proton pump inhibitors [PPIs] [11, 12] statins), and intrinsic variation in platelet function before exposure to clopidogrel (13) (14) (15) . However, it remains unclear whether these factors fully explain the variability observed in clopidogrel pharmacokinetics and pharmacodynamics, or if a significant portion of the variability is due to still unknown factors. Here, we report the variability in clopidogrel pharmacokinetics and pharmacodynamics when known factors are rigorously excluded or controlled.
Methods

Study design.
We performed a randomized, 2-period, crossover design study to assess the effects of PPIs (dexlansoprazole, lansoprazole, esomeprazole, and omeprazole) on steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers, as previously described in detail (12) . In the present study, we analyzed steady-state clopidogrel pharmacokinetics and pharmacodynamics in healthy subjects before and after clopidogrel 75 mg/day for 9 days (because repeated daily doses of clopidogrel 75 mg achieve steady-state inhibition of ADP-induced platelet aggregation between days 3 and 7 [16, 17] ) in the absence of any PPIs. This study was conducted according to the World Medical Association Declaration of Helsinki, the International Conference on Harmonization Harmonized Tripartite Guideline for Good Clinical Practice, and local regulations. Enrollment criteria. Key enrollment criteria are summarized in Online Table 1 . In brief, healthy subjects, homozygous for CYP2C19 extensive metabolizer genotype (i.e., non-carriers of CYP2C19 *2, *3, *4, *5, *6, *7, *8, *9, *10, or *17), aged 18 to 55 years, with a body mass index (BMI) between 18 and 30 kg/m 2 , and free of nicotine for 6 weeks, prescription drugs for 4 weeks, over-the-counter drugs (OTC) for 2 weeks, and caffeine and alcohol for 72 h were enrolled. All subjects found to be CYP2C19 poor, intermediate, or ultra-rapid metabolizer genotypes were deemed screen failures and were excluded. Treatment period. Enrolled subjects (cohorts of 40 subjects at a time) were confined in a clinical research unit for 10 consecutive days and nights during periods 1 and 2. Subjects fasted Ն8 h before clopidogrel dosing. Witnessed dosing of clopidogrel commenced at ϳ0800 h on days 1 through 9 of both periods. Diet, fluid, and activity control. During the confinement period, subjects received standardized meals and snacks and refrained from strenuous exercise. All subjects could consume water ad libitum except for 1 h pre-and post-drug administration (the Online Appendix for details). Genotype analysis. Genotyping of CYP2C19 alleles (*2, *3, *4, *5, *6, *7, *8, *9, *10, and *17 [C-806T]) was performed as previously described (12) . Enrolled subjects were also genotyped with respect to the following single nucleotide polymorphisms: CYP3A5 *3 and *6, ABCB1 C3435T, and PON1 rs622 (A/G), as previously described (5,12) (Online Appendix). Clopidogrel pharmacokinetics. Clopidogrel active metabolite (clopidogrel AM ) concentration in samples collected on day 9 pre-dose and at specified times through 24 h postdose were determined as previously described (12) (see Online Appendix) and used to determine the peak plasma concentration (C max ) and the area under the plasma concentration-time curve from time 0 to the time of last quantifiable concentration (AUC t ). Clopidogrel pharmacodynamics. Platelet function was measured pre-dose on days -1, 7, 8, and 9, and at 24 h after the day 9 dose. The pharmacodynamic effects of clopidogrel were evaluated by 3 platelet function tests: the vasodilatorstimulated phosphoprotein (VASP) P2Y 12 2 , were calculated to estimate the contribution of demographic, hematologic, and genetic factors to clopidogrel pharmacokinetic and pharmacodynamic endpoints while controlling for study design variables (cohort, period, and treatment group). The effects of selected polymorphisms on clopidogrel pharmacokinetics and pharmacodynamics were evaluated within analysis of variance models with fixed factors for genotype, cohort, period, and treatment group. General linear models with stepwise selection for corrected Akaike's information criterion and fixed factors for cohort, period, and treatment group were used to select demographic, hematologic, and genetic factors predictive of each of the pharmacokinetic and pharmacodynamic endpoints. Effect size of each factor was estimated using semipartial correlations, 2 . Log-transformed values of clopidogrel AM AUC t , and C max were used for all models.
Results
Subject characteristics and disposition. Five hundred fifty-two subjects were screened and 160 subjects were enrolled, as previously reported (12) . All enrolled subjects were genotyped as CYP2C19 *1/*1 extensive metabolizers and had normal hematology, clinical chemistry, and urinalysis results at enrollment. One hundred fifty-six of the 160 enrolled subjects completed the 9 days of treatment with clopidogrel 75 mg and the accompanying pharmacokinetic and pharmacodynamic measurements. Reasons for failure to complete the study were adverse event (n ϭ 2), major protocol violation (n ϭ 1), and pregnancy (n ϭ 1). Subject demographics and baseline characteristics are shown in Table 1 . Variation in clopidogrel pharmacokinetics and pharmacodynamics. Following 9 days of treatment with clopidogrel, interindividual exposure to clopidogrel AM varied widely: AUC t and C max values varied more than threefold from the 10th to the 90th percentile and the coefficients of variation (CV) were large (34% and 40%, respectively) (mean Ϯ SD: AUC t 41.3 Ϯ 14.0 ng-hr/ml; C max 39.6 Ϯ 15.9 ng/ml) (Figs 1A and 1B, Online Table 2 ). As expected, mean values for clopidogrel pharmacodynamic markers were reduced following 9 days of clopidogrel treatment (Figs. 1C to 1F, Online Table 2 ). However, as was observed with clopidogrel pharmacokinetics, clopidogrel pharmacodynamics after 9 days of treatment with clopidogrel varied widely (CVs 37%, 53%, 37%, and 32% for VASP platelet reactivity Table 2 ). This variation was not accounted for by day-to-day subject and/or assay variation, which was small as judged by intraclass correlation coefficients of Ͼ80% (Online Table 3 , Online Fig. 1 ).
Using the cutpoints suggested by an international consensus group (2), high on-treatment platelet reactivity was present in 62 of 156 (40%) subjects by VASP PRI Ͼ50, 15 of 156 (10%) subjects by MPA with 5-M ADP Ͼ46, and 8 of 156 (5%) subjects by VerifyNow P2Y12 PRU Ͼ235 (Fig. 2) . A total of 45% of healthy subjects had high on-treatment platelet reactivity by at least 1 criterion. Influence of demographic, hematologic, genetic, and study design factors on clopidogrel pharmacokinetics. Table 2 summarizes the influence of factors related to subject demographics (age, sex, weight), hematology (platelet count, hematocrit), and genetics (polymorphisms of CYP3A5, ABCB1, and PON1), on clopidogrel AM pharmacokinetics (C max and AUC t ). Only age and baseline weight were significantly associated with clopidogrel AM AUC t and C max . However, correlations between clopidogrel AM AUC t and C max and subject weight and age indicated that only 5% to 6% of the variation in clopidogrel AM AUC t and C max was explained by differences in weight and age ( 2 range: 0.0525 to 0.0639) ( Table 4 ). For multivariate analysis, a general linear model with stepwise selection was used to identify demographic, hematologic, and genetic factors that independently predicted clopidogrel pharmacokinetics. The optimal model for predicting clopidogrel AM AUC t accounted for ϳ18% of the variation (adjusted r 2 ϭ 0.1789), and included age ( 2 ϭ 0.0384, p ϭ 0.0082) and weight ( 2 ϭ 0.0372, p ϭ 0.0092) as factors (Fig. 3 , Online Table 5 ), whereas sex, platelet count, hematocrit, and the indicated polymorphisms in CYP3A5, ABCB1, and PON1 were not significantly associated with clopidogrel AM AUC t . Likewise, the optimal model for predicting clopidogrel AM C max accounted for ϳ16% of the variation (adjusted r 2 ϭ 0.1552) and included age ( 2 ϭ 0.0315, p ϭ 0.0179) and weight ( 2 ϭ 0.0328, p ϭ 0.0157) (Fig. 3 , Online Table 5 ). Thus, for both clopidogrel AM AUC t and C max , ϳ82% of the variation remained unexplained. Influence of demographic, hematologic, and genetic factors on clopidogrel pharmacodynamics. Table 3 summarizes the results of analysis of the influence of clopidogrel AM AUC t and C max and factors related to subject demographics, hematology, genetics, and baseline (pre-treatment) VASP PRI on the on-treatment (day 9) VASP PRI. As expected, clopidogrel AM AUC t and C max were predictive of VASP PRI (r 2 ϭ 0.3820 and 0.2329, respectively; p Ͻ 0.0001 each) (Table 3) . Like clopidogrel AM pharmacokinetic endpoints, VASP PRI did not differ significantly when analyzed according to polymorphisms in CYP3A5, ABCB1, and PON1 (Table 3, Online Table 6 ). 
Figure 2 Overlap of High On-Treatment Platelet Reactivity
As determined by 3 assays in healthy, homozygous CYP2C19 extensive metabolizer genotype subjects, free of nicotine, alcohol, prescription, and overthe-counter medication, with witnessed clopidogrel 75 mg/day treatment for 9 days. MPA ϭ maximum platelet aggregation; other abbreviations as in Figure 1 .
Effects of Demographic, Hematologic, and Genetic Factors on Clopidogrel AM Pharmacokinetics (AUC t and C max ). The optimal multivariable model for predicting VASP PRI (adjusted r 2 ϭ 0.4755 for model) (Fig. 3 ) included clopidogrel AM AUC t ( 2 ϭ 0.3579, p Ͻ 0.0001), with very small contributions from platelet count ( 2 ϭ 0.0195, p ϭ 0.0179), and pre-treatment VASP PRI ( 2 ϭ 0.0187, p ϭ 0.0205). Evaluation of independent variables that may contribute to clopidogrel's effect on platelet function as measured by VerifyNow P2Y12 PRU, VerifyNow percent inhibition, and by MPA with 5-and 20-M ADP is shown in Table 3 . Clopidogrel AM AUC t and C max , VASP PRI, hematocrit, and sex were each significantly associated with VerifyNow PRU, MPA with 5-M ADP, and MPA with 20-M ADP (Table 3) . Subject age was significantly associated with VerifyNow PRU (Table 3) . A modest (r 2 ϭ 0.2603), but highly significant (p Ͻ 0.0001) association, was found between pre-treatment VerifyNow PRU and on-treatment VerifyNow PRU. Pre-treatment MPA to 5-M ADP was only weakly associated with on-treatment MPA to 5-M ADP (Table 3) .
VerifyNow PRU, MPA with 5-M ADP, and MPA with 20-M ADP were not correlated with polymorphisms in CYP3A5, ABCB1, and PON1 (Table 3, Online Table 7 ).
The optimal multivariable models for predicting VerifyNow PRU and VerifyNow percent inhibition included factors for clopidogrel AM pharmacokinetics, VASP PRI, hematocrit, and for VerifyNow PRU, pre-treatment VerifyNow PRU. Together these factors explained 65% and 57% of the variation in VerifyNow PRU and VerifyNow percent inhibition, respectively (r 2 ϭ 0.6500 and 0.5738, respectively) (Fig. 3, Online Table 8 ). C max , although highly correlated with clopidogrel AM AUC t , was a slightly better predictor of VerifyNow percent inhibition than clopidogrel AM AUC t , and was therefore included in the final model for prediction of VerifyNow percent inhibition. The optimal multivariable model for predicting MPA to 5-M ADP included factors for clopidogrel AM AUC t , baseline hematocrit, and pretreatment MPA with 5-M ADP and accounted for 35% of variation in MPA with 5-M ADP (r 2 ϭ 0.3519) (Fig. 3 , Online Table 8 ). Likewise, the optimal model to predict MPA with 20-M ADP included factors for clopidogrel AM AUC t , VASP PRI, sex, and pre-treatment MPA with 20-M ADP and accounted for 44% of variation in MPA with 20-M ADP (r 2 ϭ 0.4357) (Fig. 3 , Online Table 8 ).
Discussion
The main findings of this study are the following. 1) Despite the rigorous elimination of variation in CYP2C19 polymorphisms, compliance, diet, nicotine, and prescription and nonprescription medications (including PPIs and statins), clopidogrel pharmacokinetics and pharmacodynamics still varied widely. 2) Differences within the study population with respect to age, weight, sex, platelet count, hematocrit, and polymorphisms in CYP3A5, ABCB1, or PON1 accounted for only ϳ18% of the variability in clopidogrel AM AUC t , and C max , leaving ϳ82% of the variability unexplained. 3) These factors, together with each subject's clopidogrel AM AUC t and C max , accounted for only ϳ48% of the variability in ADP-induced signaling through P2Y 12 as measured by VASP phosphorylation, leaving ϳ52% of the variability unexplained. 4) Differences in the preceding factors, clopidogrel AM AUC t , and C max , and P2Y 12 signaling together accounted for 35% to 65% of the variability in platelet aggregation in platelet-rich plasma or whole blood, leaving 35% to 65% of the variability unexplained. 5) Pretreatment variability in platelet reactivity was a significant, albeit minor, contributor to on-treatment platelet reactivity. 6) Variation in clopidogrel pharmacokinetics and pharmacodynamic parameters were not associated with polymorphisms in CYP3A5, ABCB1, or PON1. Because patients with reduced platelet inhibition during clopidogrel treatment have an increased risk for major adverse cardiovascular events (2), the present findings, summarized diagrammatically in Figure 3 , are important. For example, the presently described wide variability in clopidogrel pharmacokinetics and pharmacodynamics independent of known factors (including single nucleotide polymorphisms, noncompliance, diet, smoking, and co-medications) provides a pharmacological explanation for the relative lack of effect of clopidogrel in nonsmokers (10) and strongly suggests that therapeutic strategies based on the CYP2C19*2 polymorphism (20) will not eliminate the increased risk for major adverse cardiovascular events in patients with high ontreatment platelet reactivity. The Food and Drug Administration has issued a "black box warning" for clopidogrel (17, 21) that alternative treatment should be considered in patients identified as CYP2C19 poor metabolizers based on the CYP2C19 polymorphism. However, our study demonstrates that even in healthy homozygous CYP2C19 extensive metabolizer subjects free of nicotine, alcohol, prescription, and OTC medications, and with witnessed compliance to study medication, there is a high frequency of poor response to clopidogrel (45% had high on-treatment platelet reactivity by at least 1 criterion). In the present study, rigorous measures were taken to eliminate or control potential contributors to clopidogrel variability, thereby allowing us to determine if the observed variation might be explained by measurable demographic factors. However, clopidogrel AM pharmacokinetics varied widely despite these controls and adjustments for demographics (Fig. 1, Online Table 2 ), leaving the source of ϳ82% of the variability unknown. Likely contributors to this variation in clopidogrel pharmaEffects of Individual Demographic, Hematologic, and Genetic Factors on Clopidogrel Pharmacodynamics Frelinger et al. February 26, 2013:872-9 Clopidogrel Response Variability cokinetics include genetic factors (other than CYP2C19 polymorphisms) and nongenetic sources of variation in clopidogrel absorption and metabolism. Multiple studies confirmed a role for CYP2C19*2 in both the laboratory and clinical response to clopidogrel (2) . A genome-wide association study found that variation in platelet function following clopidogrel administration was highly heritable (22) , but the CYP2C19*2 polymorphism accounted for (only) ϳ12% of the variation in platelet aggregation (22) . The high heritability estimate suggests that additional genetic variants may contribute to clopidogrel response variability. Bouman et al. (5) proposed that PON1 plays a major role in clopidogrel metabolism and that a common polymorphism in PON1, rs662, affects the rate of clopidogrel AM formation. However, other investigators found no significant effect of the PON1 rs662 polymorphism on clopidogrel pharmacokinetics or pharmacodynamics (23) (24) (25) (26) . In the present study, the PON1 rs662 polymorphism was not significantly associated with clopidogrel pharmacokinetic or pharmacodynamic endpoints (Tables 2 and 3, Online Tables 4, 6 , and 7). This finding adds to and complements previous findings (23) (24) (25) (26) , because in the present study, possible confounding factors (subject health, co-medications, smoking, diet, and CYP2C19 genotype) were eliminated or controlled by study design. Likewise, and in contrast to some reports (6, 8, 18, 19) , in the present, rigorously controlled study, no associations were observed between polymorphisms in ABCB1 (C3435T) or CYP3A5 (*3) and clopidogrel pharmacokinetic or pharmacodynamic endpoints (Tables 2 and 3,  Online Tables 4, 6 , and 7).
Considering the small number of biochemical steps between ADP binding to P2Y 12 and changes in VASP phosphorylation (27) , a surprising result of the present study is that the measured clopidogrel pharmacokinetics explain only ϳ48% of the variability in clopidogrel pharmacodynamics as measured by the VASP assay. Potential explanations for this phenomenon include quantitative or qualitative differences in signaling molecules between P2Y 12 and VASP, such as G ␣i , adenylyl cyclase, or protein kinase A.
Clopidogrel AM AUC t and C max values also had an unexpectedly small influence on variation in platelet aggregation measured by LTA or VerifyNow, accounting for Ͻ40% of the variation in platelet aggregation assays (Table 3) . This may be explained in part by the fact that platelet aggregation is well downstream from the platelet ADP receptor, P2Y 12 (the molecular target for clopidogrel's active metabolite) and is dependent on glycoprotein IIb-IIIa (integrin ␣IIb␤3) receptor density, fibrinogen, platelet concentration, and cell-cell contact. VASP phosphorylation is distal to signaling through P2Y 12 , but upstream from glycoprotein IIb-IIIa activation and platelet aggregation (Fig. 3) . Because signaling through P2Y 12 , as measured by VASP phosphorylation, varied from that predicted on the basis of clopidogrel AM pharmacokinetics, we evaluated the ability of VASP PRI to independently predict platelet aggregation measured by 5-and 20-M ADP-induced LTA and the VerifyNow P2Y12 assay. VASP PRI accounted for ϳ4% and ϳ14% of the variation in VerifyNow PRU and VerifyNow percent inhibition, respectively, and ϳ2% of the variation in MPA to 20-M ADP (Fig. 3 , Online Table 8 ) independent of pharmacokinetics and other predictors. Thus, variation in signaling between P2Y 12 and VASP phosphorylation accounts for a small portion of the variation in these platelet aggregation endpoints; a portion of the remaining variation may be due to variation in signaling distal to VASP.
Approximately 35%, 44%, and 65% of the variation in 5-and 20-M ADP-induced LTA, and the VerifyNow P2Y12 assay, respectively, could be explained by identified factors in the present study (Fig. 3) . In an analysis of the POPular (Do Platelet Function Assays Predict Clinical Outcomes in Clopidogrel-Pretreated Patients Undergoing Elective PCI) study, Bouman et al. (28) demonstrated that, in addition to the CYP2C19*2 genotype, high on-treatment platelet reactivity could be independently predicted by clinical factors (demographics, disease, drug use, etc.). When these clinical factors were combined with CYP2C19*2 polymorphism as predictors, 13.0%, 15.2%, and 20.6% of the variability in 5-and 20-M ADP-induced LTA, and the VerifyNow P2Y12 assay, respectively, could be explained (28) . However, the level of clopidogrel AM , arguably the most critical determinant of the response to clopidogrel, was not measured in POPular. Thus, in POPular (unlike the present study), it was not possible to estimate the total proportion of clopidogrel response variation that could be explained by all known factors.
We, and others, have previously reported that pretreatment platelet reactivity is a predictor of platelet reactivity during clopidogrel treatment (13) (14) (15) . Here, we demonstrate that when known contributors to variation in clopidogrel's pharmacodynamic response are removed, intrinsic pre-treatment platelet reactivity remains a significant, albeit modest (Table 3) , predictor of on-treatment variation, accounting for ϳ2% of variation in platelet reactivity as measured by 3 independent assays. Finally, the proportion of variance due to error in these measures may be nontrivial, although the very high intraclass correlations (Ͼ0.8) (Online Table 3 ) suggests intraindividual variability (which includes assay error) is low. Study limitations. First, this study was conducted in confined healthy volunteers, not patients, but this enabled us to rigorously control for co-medications, diet, smoking, clopidogrel compliance, etc., and to exclude known disease as a contributor to variability. Furthermore, the presently described high degree of variability in clopidogrel response in healthy volunteers would likely only be higher in patients with activated platelets due to acute coronary syndromes or additional co-morbidities such as diabetes mellitus. Second, for uniformity, this study included only homozygous CYP2C19 extensive metabolizers; consequently, our conclusions are limited to this population. 
